Environmental inhibitors of 11β-hydroxysteroid dehydrogenase type 2

Toxicology

Volumn 285, Issue 3, 2011, Pages 83-89

  Ma, Xue ^a,b   Lian, Qing Quan ^c   Dong, Qiang ^a   Ge, Ren Shan ^b,c  

^a SICHUAN UNIVERSITY   (China)

^b POPULATION COUNCIL   (United States)

^c THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

11 Hydroxysteroid dehydrogenase type 2; Alkylphenols; Glucocorticoid; Gossypol; Inhibitor; Organotins; Perfluorinated substances; Phthalates; Toxicity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALKYLPHENOL; ENDOCRINE DISRUPTOR; GLYCYRRHIZA EXTRACT; GOSSYPOL; ORGANOTIN COMPOUND; PERFLUORO COMPOUND; PHTHALIC ACID DERIVATIVE;

ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; ENDOTHELIUM, VASCULAR; EPIDIDYMIS; FEMALE; GLYCYRRHIZA; GOSSYPOL; HUMANS; HYDROCORTISONE; KIDNEY; MALE; ORGANOTIN COMPOUNDS; PLACENTA; PREGNANCY; TESTIS;

GLYCYRRHIZA;

EID: 79957836054     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.04.007     Document Type: Review

References (88)

1. Adeeko A., Li D., Forsyth D.S., Casey V., Cooke G.M., Barthelemy J., Cyr D.G., Trasler J.M., Robaire B., Hales B.F. Effects of in utero tributyltin chloride exposure in the rat on pregnancy outcome. Toxicol. Sci. 2003, 74:407-415.
2. Agarwal A.K., Monder C., Eckstein B., White P.C. Cloning and expression of rat cDNA encoding corticosteroid 11β-dehydrogenase. J. Biol. Chem. 1989, 264:18939-18943.
3. Agarwal A.K., Tusie-Luna M.T., Monder C., White P.C. Expression of 11β-hydroxysteroid dehydrogenase using recombinant vaccinia virus. Mol. Endocrinol. 1990, 4:1827-1832.
4. Agarwal A.K., Mune T., Monder C., White P.C. NAD(+)-dependent isoform of 11 beta-hydroxysteroid dehydrogenase. Cloning and characterization of cDNA from sheep kidney. J. Biol. Chem. 1994, 269:25959-25962.
5. Albro P.W., Corbett J.T., Schroeder J.L., Jordan S., Matthews H.B. Pharmacokinetics, interactions with macromolecules and species differences in metabolism of DEHP. Environ. Health Perspect. 1982, 45:19-25.
6. Albro P.W., Chapin R.E., Corbett J.T., Schroeder J., Phelps J.L. Mono-2-ethylhexyl phthalate, a metabolite of di-(2-ethylhexyl) phthalate, causally linked to testicular atrophy in rats. Toxicol. Appl. Pharmacol. 1989, 100:193-200.
7. Alfaidy N., Gupta S., DeMarco C., Caniggia I., Challis J.R. Oxygen regulation of placental 11 beta-hydroxysteroid dehydrogenase 2: physiological and pathological implications. J. Clin. Endocrinol. Metab. 2002, 87:4797-4805.
8. Arriza J.L., Weinberger C., Cerelli G., Glaser T.M., Handelin B.L., Housman D.E., Evans R.M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 1987, 237:268-275.
9. Atanasov A.G., Nashev L.G., Tam S., Baker M.E., Odermatt A. Organotins disrupt the 11beta-hydroxysteroid dehydrogenase type 2-dependent local inactivation of glucocorticoids. Environ. Health Perspect. 2005, 113:1600-1606.
10. Aufdenblatten M., Baumann M., Raio L., Dick B., Frey B.M., Schneider H., Surbek D., Hocher B., Mohaupt M.G. Prematurity is related to high placental cortisol in preeclampsia. Pediatr. Res. 2009, 65:198-202.
11. Austin M.E., Kasturi B.S., Barber M., Kannan K., MohanKumar P.S., MohanKumar S.M. Neuroendocrine effects of perfluorooctane sulfonate in rats. Environ. Health Perspect. 2003, 111:1485-1489.
12. Benediktsson R., Calder A.A., Edwards C.R., Seckl J.R. Placental 11 beta-hydroxysteroid dehydrogenase: a key regulator of fetal glucocorticoid exposure. Clin. Endocrinol. (Oxf.) 1997, 46:161-166.
13. Bhosle N.B., Garg A., Jadhav S., Harjee R., Sawant S.S., Venkat K., Anil A.C. Butyltins in water, biofilm, animals and sediments of the west coast of India. Chemosphere 2004, 57:897-907.
14. Borst J.G., Ten Holt S.P., De Vries L.A., Molhuysen J.A. Synergistic action of liquorice and cortisone in Addison's and Simmonds's disease. Lancet 1953, 1:657-663.
15. Brown R.W., Chapman K.E., Kotelevtsev Y., Yau J.L., Lindsay R.S., Brett L., Leckie C., Murad P., Lyons V., Mullins J.J., Edwards C.R., Seckl J.R. Cloning and production of antisera to human placental 11 beta-hydroxysteroid dehydrogenase type 2. Biochem. J. 1996, 313(Pt 3):1007-1017.
16. Caprio M., Newfell B.G., la Sala A., Baur W., Fabbri A., Rosano G., Mendelsohn M.E., Jaffe I.Z. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ. Res. 2008, 102:1359-1367.
17. Chen B.B., Lin H., Hu G.X., Su Y., Zhou H.Y., Lian Q.Q., Cai H., Hardy D.O., Gu D.Y., Ge R.S. The (+)- and (-)-gossypols potently inhibit human and rat 11beta-hydroxysteroid dehydrogenase type 2. J. Steroid Biochem. Mol. Biol. 2009, 113:177-181.
18. Christy C., Hadoke P.W., Paterson J.M., Mullins J.J., Seckl J.R., Walker B.R. 11beta-hydroxysteroid dehydrogenase type 2 in mouse aorta: localization and influence on response to glucocorticoids. Hypertension 2003, 42:580-587.
19. Claus R., Lacorn M., Welter H., Lekhkota O., Messe N., Wagner A., Bergmann M. Expression of 11beta-hydroxysteroid-dehydrogenase 2 in Sertoli cells of boar testes. Mol. Cell. Endocrinol. 2007, 272:86-92.
20. Cole T.J. Cloning of the mouse 11 beta-hydroxysteroid dehydrogenase type 2 gene: tissue specific expression and localization in distal convoluted tubules and collecting ducts of the kidney. Endocrinology 1995, 136:4693-4696.
21. Cooke G.M., Tryphonas H., Pulido O., Caldwell D., Bondy G.S., Forsyth D. Oral (gavage), in utero and postnatal exposure of Sprague-Dawley rats to low doses of tributyltin chloride. Part 1: toxicology, histopathology and clinical chemistry. Food Chem. Toxicol. 2004, 42:211-220.
22. 2OH: kinetics and mechanism of reaction with OH. Environ. Sci. Technol. 2006, 40:1862-1868.
23. Deuchar G.A., McLean D., Hadoke P.W., Brownstein D.G., Webb D.J., Mullins J.J., Chapman K., Seckl J.R., Kotelevtsev Y.V. 11beta-2 deficiency accelerates atherogenesis, causes proinflammatory changes in the endothelium in apoe-/- mice. Endocrinology 2011, 152:236-246.
24. Doyle L.W., Faber B., Callanan C., Morley R. Blood pressure in late adolescence and very low birth weight. Pediatrics 2003, 111:252-257.
25. Draper N., Stewart P.M. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J. Endocrinol. 2005, 186:251-271.
26. Edwards C.R., Stewart P.M., Burt D., Brett L., McIntyre M.A., Sutanto W.S., de Kloet E.R., Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid receptor. Lancet 1988, 2:986-989.
27. Fent K. Ecotoxicology of organotin compounds. Crit. Rev. Toxicol. 1996, 26:1-117.
28. Funder J.W., Pearce P.T., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988, 242:583-585.
29. Ge R.S., Gao H.B., Nacharaju V.L., Gunsalus G.L., Hardy M.P. Identification of a kinetically distinct activity of 11beta-hydroxysteroid dehydrogenase in rat Leydig cells. Endocrinology 1997, 138:2435-2442.
30. Ge R.S., Dong Q., Niu E.M., Sottas C.M., Hardy D.O., Catterall J.F., Latif S.A., Morris D.J., Hardy M.P. 11{beta}-Hydroxysteroid dehydrogenase 2 in rat leydig cells: its role in blunting glucocorticoid action at physiological levels of substrate. Endocrinology 2005, 146:2657-2664.
31. Ge R.S., Chen G.R., Tanrikut C., Hardy M.P. Phthalate ester toxicity in Leydig cells: developmental timing and dosage considerations. Reprod. Toxicol. 2007, 23:366-373.
32. Ge R., Huang Y., Liang G., Li X. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development. Curr. Med. Chem. 2010, 17:412-422.
33. Haeussler S., Claus R. Expression of the glucocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase 2 in pig testes cells along fetal development. Reprod. Fertil. Dev. 2007, 19:664-669.
34. Hardy M.P., Ganjam V.K. Stress, 11beta-HSD, and Leydig cell function. J. Androl. 1997, 18:475-479.
35. Hardy M.P., Gao H.B., Dong Q., Ge R., Wang Q., Chai W.R., Feng X., Sottas C. Stress hormone and male reproductive function. Cell Tissue Res. 2005, 322:147-153.
36. Holmes M.C., Abrahamsen C.T., French K.L., Paterson J.M., Mullins J.J., Seckl J.R. The mother or the fetus? 11beta-hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids. J. Neurosci. 2006, 26:3840-3844.
37. Hong D., Li X.W., Lian Q.Q., Lamba P., Bernard D.J., Hardy D.O., Chen H.X., Ge R.S. Mono-(2-ethylhexyl) phthalate (MEHP) regulates glucocorticoid metabolism through 11beta-hydroxysteroid dehydrogenase 2 in murine gonadotrope cells. Biochem. Biophys. Res. Commun. 2009, 389:305-309.
38. Hu G.X., Lin H., Sottas C.M., Morris D.J., Hardy M.P., Ge R.S. Inhibition of 11beta-hydroxysteroid dehydrogenase enzymatic activities by glycyrrhetinic acid in vivo supports direct glucocorticoid-mediated suppression of steroidogenesis in Leydig cells. J. Androl. 2008, 29:345-351.
39. Hu G.X., Lian Q.Q., Ge R.S., Hardy D.O., Li X.K. Phthalate-induced testicular dysgenesis syndrome: Leydig cell influence. Trends Endocrinol. Metab. 2009, 20:139-145.
40. Jang C., Obeyesekere V.R., Dilley R.J., Krozowski Z., Inder W.J., Alford F.P. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 2007, 92:3314-3320.
41. Kotelevtsev Y., Brown R.W., Fleming S., Kenyon C., Edwards C.R., Seckl J.R., Mullins J.J. Hypertension in mice lacking 11beta-hydroxysteroid dehydrogenase type 2. J. Clin. Invest. 1999, 103:683-689.
42. Kratschmar, D.V., Vuorinen, A., Da Cunha, T., Wolber, G., Classen-Houben, D., Doblhoff, O., Schuster, D. and Odermatt, A. Characterization of activity and binding mode of glycyrrhetinic acid derivatives inhibiting 11beta-hydroxysteroid dehydrogenase type 2. J. Steroid Biochem. Mol. Biol., in press.
43. Krozowski Z., MaGuire J.A., Stein-Oakley A.N., Dowling J., Smith R.E., Andrews R.K. Immunohistochemical localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme in human kidney and placenta. J. Clin. Endocrinol. Metab. 1995, 80:2203-2209.
44. Krozowski Z., Albiston A.L., Obeyesekere V.R., Andrews R.K., Smith R.E. The human 11 beta-hydroxysteroid dehydrogenase type II enzyme: comparisons with other species and localization to the distal nephron. J. Steroid Biochem. Mol. Biol. 1995, 55:457-464.
45. Krug A.W., Kopprasch S., Ziegler C.G., Dippong S., Catar R.A., Bornstein S.R., Morawietz H., Gekle M. Aldosterone rapidly induces leukocyte adhesion to endothelial cells: a new link between aldosterone and arteriosclerosis?. Hypertension 2007, 50:e156-e157.
46. Kyossev Z., Walker P.D., Reeves W.B. Immunolocalization of NAD-dependent 11 beta-hydroxysteroid dehydrogenase in human kidney and colon. Kidney Int. 1996, 49:271-281.
47. Lakshmi V., Monder C. Purification and characterization of the corticosteroid 11 beta-dehydrogenase component of the rat liver 11 beta-hydroxysteroid dehydrogenase complex. Endocrinology 1988, 123:2390-2398.
48. Lau C., Butenhoff J.L., Rogers J.M. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol. Appl. Pharmacol. 2004, 198:231-241.
49. Lin H., Ge R.S., Chen G.R., Hu G.X., Dong L., Lian Q.Q., Hardy D.O., Sottas C.M., Li X.K., Hardy M.P. Involvement of testicular growth factors in fetal Leydig cell aggregation after exposure to phthalate in utero. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:7218-7222.
50. Lin H., Lian Q.Q., Hu G.X., Jin Y., Zhang Y., Hardy D.O., Chen G.R., Lu Z.Q., Sottas C.M., Hardy M.P., Ge R.S. In utero and lactational exposures to diethylhexyl-phthalate affect two populations of leydig cells in male long-evans rats. Biol. Reprod. 2009, 80:882-888.
51. Liu S., Kulp S.K., Sugimoto Y., Jiang J., Chang H.L., Dowd M.K., Wan P., Lin Y.C. The (-)-enantiomer of gossypol possesses higher anticancer potency than racemic gossypol in human breast cancer. Anticancer Res. 2002, 22:33-38.
52. Marandici A., Monder C. Inhibition by glycyrrhetinic acid of rat tissue 11 beta-hydroxysteroid dehydrogenase in vivo. Steroids 1993, 58:153-156.
53. Monder C., Stewart P.M., Lakshmi V., Valentino R., Burt D., Edwards C.R. Licorice inhibits corticosteroid 11β-dehydrogenase of rat kidney and liver: in vivo and in vitro studies. Endocrinology 1989, 125:1046-1053.
54. Moore X.L., Hoong I., Cole T.J. Expression of the 11β-hydroxysteroid dehydrogenase 2 gene in the mouse. Kidney Int. 2000, 57:1307-1312.
55. Nacharaju V.L., Divald A., McCalla C.O., Yang L., Muneyyirci-Delale O. 11beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone stimulates chorionic gonadotropin secretion from human term cytotrophoblast cells differentiated in vitro. Am. J. Reprod. Immunol. 2004, 52:133-138.
56. Naray-Fejes-Toth A., Rusvai E., Denault D.L., St Germain D.L., Fejes-Toth G. Expression and characterization of a new species of 11 beta-hydroxysteroid dehydrogenase in Xenopus oocytes. Am. J. Physiol. 1993, 265:F896-F900.
57. Ohshima M., Ohno S., Nakajin S. Inhibitory effects of some possible endocrine-disrupting chemicals on the isozymes of human 11beta-hydroxysteroid dehydrogenase and expression of their mRNA in gonads and adrenal glands. Environ. Sci. 2005, 12:219-230.
58. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 2007, 115:1298-1305.
59. Pearce P.T., Lipkevicius O.R., Funder J.W. High affinity (type 1) aldosterone-binding sites in rat epididymis. Endocrinology 1986, 118:2072-2075.
60. Sang G.W., Lorenzo B., Reidenberg M.M. Inhibitory effects of gossypol on corticosteroid 11-beta-hydroxysteroid dehydrogenase from guinea pig kidney: a possible mechanism for causing hypokalemia. J. Steroid Biochem. Mol. Biol. 1991, 39:169-176.
61. Seckl J.R. Prenatal glucocorticoids and long-term programming. Eur. J. Endocrinol. 2004, 3(Suppl. 151):U49-U62.
62. Seckl J.R., Holmes M.C. Mechanisms of disease: glucocorticoids, their placental metabolism and fetal 'programming' of adult pathophysiology. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:479-488.
63. Shelley M.D., Hartley L., Fish R.G., Groundwater P., Morgan J.J., Mort D., Mason M., Evans A. Stereo-specific cytotoxic effects of gossypol enantiomers and gossypolone in tumour cell lines. Cancer Lett. 1999, 135:171-180.
64. Smith R.E., Little P.J., Maguire J.A., Stein-Oakley A.N., Krozowski Z.S. Vascular localization of the 11 beta-hydroxysteroid dehydrogenase type II enzyme. Clin. Exp. Pharmacol. Physiol. 1996, 23:549-551.
65. Soaresam A., Guieysseb B., Jeffersona B., Cartmella E., Lestera J.N. Nonylphenol in the environment: a critical review on occurrence, fate, toxicity and treatment in wastewaters. Environ. Int. 2008, 34:1033-1049.
66. Song D., Lorenzo B., Reidenberg M.M. Inhibition of 11 beta-hydroxysteroid dehydrogenase by gossypol and bioflavonoids. J. Lab. Clin. Med. 1992, 120:792-797.
67. Stewart P.M., Wallace A.M., Valentino R., Burt D., Shackleton C.H., Edwards C.R. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987, 2:821-824.
68. Stewart P.M., Whorwood C.B., Mason J.I. Type 2 11 beta-hydroxysteroid dehydrogenase in foetal and adult life. J. Steroid Biochem. Mol. Biol. 1995, 55:465-471.
69. Stewart P.M., Krozowski Z.S., Gupta A., Milford D.V., Howie A.J., Sheppard M.C., Whorwood C.B. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996, 347:88-91.
70. Stroheker T., Regnier J.F., Lassurguere J., Chagnon M.C. Effect of in utero exposure to di-(2-ethylhexyl)phthalate: distribution in the rat fetus and testosterone production by rat fetal testis in culture. Food Chem. Toxicol. 2006, 44:2064-2069.
71. Tomlinson J.W., Stewart P.M. Mechanisms of disease: selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat. Clin. Pract. Endocrinol. Metab. 2005, 1:92-99.
72. Tomlinson J.W., Walker E.A., Bujalska I.J., Draper N., Lavery G.G., Cooper M.S., Hewison M., Stewart P.M. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev. 2004, 25:831-866.
73. Volate S.R., Kawasaki B.T., Hurt E.M., Milner J.A., Kim Y.S., White J., Farrar W.L. Gossypol induces apoptosis by activating p53 in prostate cancer cells and prostate tumor-initiating cells. Mol. Cancer Ther. 2010, 9:461-470.
74. Waddell B.J., Hisheh S., Krozowski Z.S., Burton P.J. Localization of 11β-hydroxysteroid dehydrogenase types 1 and 2 in the male reproductive tract. Endocrinology 2003, 144:3101-3106.
75. Waites G.M., Wang C., Griffin P.D. Gossypol: reasons for its failure to be accepted as a safe, reversible male antifertility drug. Int. J. Androl. 1998, 21:8-12.
76. Wake D.J., Walker B.R. 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol. Cell. Endocrinol. 2004, 215:45-54.
77. White P.C., Mune T., Rogerson F.M., Kayes K.M., Agarwal A.K. 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Pediatr. Res. 1997, 41:25-29.
78. White P.C., Mune T., Rogerson F.M., Kayes K.M., Agarwal A.K. Molecular analysis of 11 beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. Steroids 1997, 62:83-88.
79. Whorwood C.B., Ricketts M.L., Stewart P.M. Epithelial cell localization of type 2 11 beta-hydroxysteroid dehydrogenase in rat and human colon. Endocrinology 1994, 135:2533-2541. (published erratum appears in Endocrinology 1995 Apr; 136(4): 1774).
80. Whorwood C.B., Mason J.I., Ricketts M.L., Howie A.J., Stewart P.M. Detection of human 11 beta-hydroxysteroid dehydrogenase isoforms using reverse-transcriptase-polymerase chain reaction and localization of the type 2 isoform to renal collecting ducts. Mol. Cell. Endocrinol. 1995, 110:R7-R12.
81. Wyrwoll C.S., Seckl J.R., Holmes M.C. Altered placental function of 11beta-hydroxysteroid dehydrogenase 2 knockout mice. Endocrinology 2009, 150:1287-1293.
82. Xiao-feng Z., Nai-qiang Q., Jing Z., Zi L., Yang Z. Di (n-butyl) phthalate inhibits testosterone synthesis through a glucocorticoid-mediated pathway in rats. Int. J. Toxicol. 2009, 28:448-456.
83. Xu L., Krenitsky D.M., Seacat A.M., Butenhoff J.L., Anders M.W. Biotransformation of N-ethyl-N-(2-hydroxyethyl)perfluorooctanesulfonamide by rat liver microsomes, cytosol, and slices and by expressed rat and human cytochromes P450. Chem. Res. Toxicol. 2004, 17:767-775.
84. Xu P., Ye W., Jen R., Lin S.H., Kuo C.T., Lin Y.C. Mitogenic activity of zeranol in human breast cancer cells is enhanced by leptin and suppressed by gossypol. Anticancer Res. 2009, 29:4621-4628.
85. Zhang Y., Lin L., Cao Y., Chen B., Zheng L., Ge R.S. Phthalate levels and low birth weight: a nested case-control study of Chinese newborns. J. Pediatr. 2009, 155:500-504.
86. Zhao B., Chu Y., Huang Y., Hardy D.O., Lin S., Ge R.S. Structure-dependent inhibition of human and rat 11beta-hydroxysteroid dehydrogenase 2 activities by phthalates. Chem. Biol. Interact. 2010, 183:79-84.
87. Zhao, B., Lian, Q.Q., Chu, Y., Hardy, D.O., Li, X.K. and Ge, R.S. The inhibition of human and rat 11beta-hydroxysteroid dehydrogenase 2 by perfluoroalkylated substances. J. Steroid Biochem. Mol. Biol., in press.
88. Zheng L., Dong G.H., Jin Y.H., He Q.C. Immunotoxic changes associated with a 7-day oral exposure to perfluorooctanesulfonate (PFOS) in adult male C57BL/6 mice. Arch. Toxicol. 2009, 83:679-689.